Who is sponsoring NCT02547363?

NCT02547363 is sponsored by LEO Pharma.

What condition does NCT02547363 study?

NCT02547363 studies Actinic Keratosis.

What drugs are being tested in NCT02547363?

Interventions: LEO 43204 gel, Vehicle gel.

What is the status of NCT02547363?

NCT02547363 is currently COMPLETED.

Last reviewed 2025-02-21 · How we verify

Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up

NCT02547363 Phase 3 COMPLETED Results posted

The objective of the trial is to compare the short term efficacy of LEO 43204 gel with vehicle gel in AK on the balding scalp when applied topically once daily for 3 consecutive days as field treatment.

Details

Lead sponsor	LEO Pharma
Phase	Phase 3
Status	COMPLETED
Enrolment	373
Start date	2015-11
Completion	2017-08

Conditions

Actinic Keratosis

Interventions

LEO 43204 gel
Vehicle gel

Primary outcomes

Percentage of Participants With Complete Clearance of Actinic Keratosis (AK) — At Week 8
The number of clinically visible actinic keratosis lesions (AKs) identified in the treatment area was recorded at Day 1 (baseline), Week 4 and Week 8. Complete clearance was defined as no clinically visible AKs in the treatment area.

Countries

United States